We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.72%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$108M
AUM Growth
-$14.5M
Cap. Flow
-$5.64M
Cap. Flow %
-5.21%
Top 10 Hldgs %
67.6%
Holding
63
New
4
Increased
7
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$736K
2
XOM icon
ExxonMobil
XOM
+$681K
3
CORT icon
Corcept Therapeutics
CORT
+$657K
4
BDSX icon
Biodesix
BDSX
+$497K
5
CSTL icon
Castle Biosciences
CSTL
+$446K

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$4.8M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$1.69M
3
PXD
Pioneer Natural Resource Co.
PXD
+$998K
4
BMY icon
Bristol-Myers Squibb
BMY
+$689K
5
OVV icon
Ovintiv
OVV
+$503K

Sector Composition

Rank Sector Weight
1 Healthcare 94.57%
2 Energy 5.43%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNY icon
26
Progyny
PGNY
$2.51B
$629K 0.58%
22,000
– –
TXG icon
27
10x Genomics
TXG
$5.49B
$584K 0.54%
30,000
– –
KNSA icon
28
Kiniksa Pharmaceuticals
KNSA
$4.83B
$560K 0.52%
30,000
– –
KALV
29
DELISTED
KalVista Pharmaceuticals
KALV
$542K 0.5%
46,000
– –
CYTK icon
30
Cytokinetics
CYTK
$10.9B
$542K 0.5%
10,000
– –
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$537K 0.5%
14,000
-4,000
-22% -$181K
HALO icon
32
Halozyme
HALO
$9.21B
$524K 0.48%
10,000
– –
CHRS icon
33
Coherus Oncology
CHRS
$217M
$467K 0.43%
270,000
– –
KPTI icon
34
Karyopharm Therapeutics
KPTI
$150M
$408K 0.38%
31,322
– –
ARVN icon
35
Arvinas
ARVN
$517M
$399K 0.37%
15,000
– –
SRPT icon
36
Sarepta Therapeutics
SRPT
$1.81B
$395K 0.37%
2,500
– –
XENE icon
37
Xenon Pharmaceuticals
XENE
$6.5B
$390K 0.36%
10,000
– –
AXDX
38
DELISTED
Accelerate Diagnostics
AXDX
$381K 0.35%
325,239
– –
SWTX
39
DELISTED
SpringWorks Therapeutics
SWTX
$377K 0.35%
10,000
– –
CGEM icon
40
Cullinan Oncology
CGEM
$1.09B
$349K 0.32%
20,000
-5,114
-20% -$109K
NVCR icon
41
NovoCure
NVCR
$1.84B
$343K 0.32%
+20,000
New +$352K
AXSM icon
42
Axsome Therapeutics
AXSM
$11.6B
$322K 0.3%
4,000
– –
KROS icon
43
Keros Therapeutics
KROS
$210M
$320K 0.3%
7,000
– –
BLUE
44
DELISTED
bluebird bio
BLUE
$306K 0.28%
15,560
-500
-3% -$10K
FOLD
45
DELISTED
Amicus Therapeutics
FOLD
$278K 0.26%
28,000
– –
BHVN
46
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$256K 0.24%
7,365
– –
BCRX icon
47
BioCryst Pharmaceuticals
BCRX
$2.34B
$247K 0.23%
40,000
+20,000
+100% +$110K
XNCR icon
48
Xencor
XNCR
$1.4B
$233K 0.22%
12,300
– –
WVE icon
49
Wave Life Sciences
WVE
$1.11B
$200K 0.18%
40,000
– –
GTHX
50
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$182K 0.17%
80,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Birchview Capital held 63 positions worth $108M, down 12% from $123M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Birchview Capital withdrew a net $5.64M in Q2 2024, closing 3 positions and reducing 9 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $1.69M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Energy and Consumer Staples.

Against the trend, Birchview Capital opened a new position in ExxonMobil worth $673K.

  • Birchview Capital's largest Q2 2024 buy was ExxonMobil: 5,849 shares worth $673K.
  • Birchview Capital added most to Prothena Corp in Q2 2024, an estimated $736K increase.
  • Birchview Capital's biggest Q2 2024 reduction was Neurocrine Biosciences, cutting an estimated $4.8M.
  • Birchview Capital fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $1.69M.
  • Birchview Capital's ten largest holdings make up 68% of its $108M portfolio in Q2 2024.
  • Birchview Capital opened 4 new positions and closed 3 in Q2 2024.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $108M.

Based on Birchview Capital's 13F filing for Q2 2024, filed 13 Aug 2024.